336 related articles for article (PubMed ID: 32902794)
1. Implications of flavonoids as potential modulators of cancer neovascularity.
Liskova A; Koklesova L; Samec M; Varghese E; Abotaleb M; Samuel SM; Smejkal K; Biringer K; Petras M; Blahutova D; Bugos O; Pec M; Adamkov M; Büsselberg D; Ciccocioppo R; Adamek M; Rodrigo L; Caprnda M; Kruzliak P; Kubatka P
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3079-3096. PubMed ID: 32902794
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL; Chen HH; Zheng LL; Sun LP; Shi L
Signal Transduct Target Ther; 2023 May; 8(1):198. PubMed ID: 37169756
[TBL] [Abstract][Full Text] [Related]
5. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.
Tysome JR; Lemoine NR; Wang Y
Curr Opin Mol Ther; 2009 Dec; 11(6):664-9. PubMed ID: 20072943
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
7. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
Haiaty S; Rashidi MR; Akbarzadeh M; Maroufi NF; Yousefi B; Nouri M
IUBMB Life; 2020 May; 72(5):825-841. PubMed ID: 32026601
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
10. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
12. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
Olejarz W; Kubiak-Tomaszewska G; Chrzanowska A; Lorenc T
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823989
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
14. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis in spontaneous tumors and implications for comparative tumor biology.
Benazzi C; Al-Dissi A; Chau CH; Figg WD; Sarli G; de Oliveira JT; Gärtner F
ScientificWorldJournal; 2014; 2014():919570. PubMed ID: 24563633
[TBL] [Abstract][Full Text] [Related]
16. Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2.
Bräutigam J; Bischoff I; Schürmann C; Buchmann G; Epah J; Fuchs S; Heiss E; Brandes RP; Fürst R
J Mol Cell Cardiol; 2019 Oct; 135():97-108. PubMed ID: 31381906
[TBL] [Abstract][Full Text] [Related]
17. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
18. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
19. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Gacche RN; Meshram RJ
Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
